UK scientists working to find a cure for HIV
IIIIIsometimes be diagnosed with an ultrasound test. Babies with microcephaly can have a range of problems, including: • Seizures/fits • Developmental delay • Intellectual disability • Problems with movement
and balance • Feeding problems • Hearing loss • Visions problems • Severe microcephaly can be life-threatening Microcephaly is a lifelong condition, with no known cure or standard treatment Microcephaly can range from mild to severe Babies who develop microcephaly may not live to full term, may be born prematurely, may be stillborn or may survive but with lifelong disability. Babies with microcephaly will need close monitoring, and regular check-ups with a health-care provider to monitor their growth and development. A COLLABORATION between some of the top biomedical researchers in the United Kingdom (UK) may be making progress towards finding a cure for HIV.
This month marks six years since five leading research establishments agreed to cooperate to try to find a solution to one of the world’s greatest health challenges.
HIV is a virus infection that is treatable using antiretroviral therapy (ART). Essentially, ART works by stopping the HIV virus from spreading and gives the body’s immune system a chance to recover.
However, ART cannot cure HIV and if therapy stops, the virus will return.
The new research, which is still in its early stages, involves using medication that encourages the body’s immune system to fight and eradicate the disease.
Only 50 people are involved in the trial at this stage, but The Sunday Times reported on growing hopes for an eventual cure by citing the case of one of them, a 44-year-old London man who contracted HIV and has since undergone treatment. The paper reports that early tests have found that the virus is now “undetectable” in his blood.
However, the report also makes clear that the apparent absence of the virus could be attributable to the conventional medications that he has also been taking.
The medical consortium was the idea of Mark Samuels, managing director of the National Office for Clinical Research Infrastructure (NOCRI), part of England’s National Institute for Health Research. He brought together leading doctors, scientists and mathematicians from the universities of Oxford and Cambridge, Imperial College London, King’s College London and University College London.
At a meeting in October 2010, they agreed to put academic rivalry aside and contribute their expertise to finding a cure for HIV. Each member present agreed that they could provide a part of the jigsaw needed to find a cure, but could not achieve this in isolation, according to Mark Samuels.
He says in a statement: “The competitive nature of the relationship between Oxford and Cambridge, spanning 800 years, is widely known, but there is also competition running across all these leading universities, particularly in terms of vying for research funding.
“Yet here was an opportunity to put that competition aside, and collaborate on a global health challenge. As a result, the Medical Research Council awarded one of the first joint grants to these five leading biomedical research institutions.
“And in return each research centre provides its expertise to complete the jigsaw needed to find a cure for HIV – from patients, to the right doctors, the right diagnostic technology, the mathematician to analyse results and so on. CHERUB was born.”
WHAT IS CHERUB?
CHERUB stands for Collaborative HIV Eradication of Viral Reservoirs: UK BRC (biomedical research centres).
The joint study, known as ‘Kick and Kill’, involves researchers activating HIVinfected cells which are ‘asleep’ using a cancer drug, which kickstarts the immune system into killing the HIV virus.
In a statement, Professor Jonathan Weber, chairman of CHERUB Scientific Steering Committee and director of research for the Faculty of Medicine at Imperial College London, said: “CHERUB has made great progress since it was born six years ago. We are now actively recruiting patients to test the ‘Kick and Kill’ theory as we have seen promising results in the lab.
“NOCRI was instrumental to this research starting. We are all thoroughly committed to finding a cure for HIV, but if the collaboration between this set of HIV researchers had not been prompted at that meeting six years ago, this simply would not have happened.”
The early trial results should be treated with caution as they have not yet been published in a peer-reviewed journal.
Commenting in a statement, Ian Green, chief executive of Terrence Higgins Trust, says: “HIV treatment currently focuses on reducing the amount of HIV in the blood to ‘undetectable’ levels, meaning the patient stays well and the virus cannot be transmitted. However, there is still no cure for HIV, and we welcome this ambitious study which looks to eradicate the virus completely from the bodies of people living with HIV, instead of suppressing it. It’s very early days, but we hope the results will help future studies on the way to finding a cure in years to come.
“Until that time, it is still important that we continue to work towards ending HIV transmission and encouraging regular testing as we know that early diagnosis and effective treatment mean people living with HIV can expect long and healthy lives, and won’t transmit the virus to others.”